Literature DB >> 19816521

Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis.

K Xu1, Q Ding, Z Fang, J Zheng, P Gao, Y Lu, Y Zhang.   

Abstract

Hypoxia-inducible factor-1alpha (HIF-1alpha) is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC). To better understanding of the role of HIF-1alpha in the tumorigenicity of RCC, we used short-hairpin RNA (shRNA) interference to inhibit HIF-1alpha expression in the human renal cancer cell line, Caki-1 and OS-RC-2. Silencing of HIF-1alpha significantly reduced the expression of HIF-1alpha in both of renal cancer cell lines. In vitro downregulation of HIF-1alpha inhibited Caki-1 and OS-RC-2 cell growth, migration and invasion. The results further showed that HIF-1alpha silencing resulted in caspase-dependent apoptosis of Caki-1 and OS-RC-2 through regulation of PI3K/Akt pathway and Bcl-2-related proteins expression. In vivo animal studies showed that tumor growth was significantly inhibited in HIF-1alpha shRNA-transfected RCC. Intratumor gene therapy with polyethylenimine-loaded HIF-1alpha shRNA also resulted in tumor growth suppression. Thus, this study demonstrates that downregulation of HIF-1alpha could suppress tumorigenicity of RCC through induction of apoptosis, and HIF-1alpha shRNA may be a promising strategy for the treatment of RCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816521     DOI: 10.1038/cgt.2009.66

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  13 in total

1.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 2.  Hypoxia, stem cells and bone tumor.

Authors:  Wen Zeng; Rong Wan; Yuehuan Zheng; Shree Ram Singh; Yiyong Wei
Journal:  Cancer Lett       Date:  2011-09-29       Impact factor: 8.679

3.  Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.

Authors:  Yosui Tamaki; Yukiomi Nakade; Taeko Yamauchi; Yuichi Makino; Shiro Yokohama; Mitsuyoshi Okada; Kazunobu Aso; Hiroyuki Kanamori; Tomohiko Ohashi; Ken Sato; Haruhisa Nakao; Masakazu Haneda; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2012-08-14       Impact factor: 7.527

Review 4.  The role of HIF1α in renal cell carcinoma tumorigenesis.

Authors:  Lorraine J Gudas; Leiping Fu; Denise R Minton; Nigel P Mongan; David M Nanus
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

5.  Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinoma.

Authors:  Zhizhong Xu; Guobo Shen; Xiangying Xia; Xinyu Zhao; Peng Zhang; Huanhuan Wu; Qingfa Guo; Zhiyong Qian; Yuquan Wei; Shufang Liang
Journal:  J Transl Med       Date:  2011-04-23       Impact factor: 5.531

6.  Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation.

Authors:  Jessica E S Bohonowych; Shuping Peng; Udhayakumar Gopal; Michael W Hance; Shane B Wing; Kelley M Argraves; Karen Lundgren; Jennifer S Isaacs
Journal:  BMC Cancer       Date:  2011-12-15       Impact factor: 4.430

7.  Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1α expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.

Authors:  Jing Zhang; Hua Guo; Jin-Shui Zhu; Yu-Chen Yang; Wei-Xiong Chen; Ni-Wei Chen
Journal:  Oncol Lett       Date:  2014-03-11       Impact factor: 2.967

8.  Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis.

Authors:  Man-Li Li; You-Zhi Xu; Wen-Jie Lu; Yong-Huai Li; Shi-Sheng Tan; Hong-Jun Lin; Tian-Ming Wu; Yan Li; Si-Ying Wang; Ying-Lan Zhao
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

9.  Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment.

Authors:  Dawei Tian; Yan Sun; Yang Yang; Mingde Lei; Na Ding; Ruifa Han
Journal:  Onco Targets Ther       Date:  2013-04-18       Impact factor: 4.147

10.  WSB1 promotes tumor metastasis by inducing pVHL degradation.

Authors:  Jung Jin Kim; Seung Baek Lee; Jinsung Jang; Sang-Yeop Yi; Sun-Hyun Kim; Sang-Ah Han; Jong-Min Lee; Seo-Yun Tong; Nicole D Vincelette; Bowen Gao; Ping Yin; Debra Evans; Dong Wook Choi; Bo Qin; Tongzheng Liu; Haoxing Zhang; Min Deng; Jin Jen; Jun Zhang; Liewei Wang; Zhenkun Lou
Journal:  Genes Dev       Date:  2015-11-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.